FG Onco Lapatinib
Pharmacogenetics of lapatinib treatment
Why undergoing this examination?
Lapatinib is a medication used in the chemotherapy of breast cancer and other solid tumors. It belongs to the group of kinase inhibitors, which act by blocking the action of the abnormal protein that signals tumor cells to multiply. Several scientific studies show that different HLA (human leukocyte antigen) polymorphisms within the major histocompatibility complex (MHC) are strongly associated with the hepatotoxicity of lapatinib treatment. This hepatotoxicity can appear within a few days or several months after the start of treatment.
What is this exam?
The FG Onco Lapatinib genetic profile evaluates whether the patient carries the HLA alleles DQA102:01 and DRB107:01. The purpose of the test is to identify those patients with an increased risk of developing serious side effects, especially hepatotoxicity, during lapatinib treatment.
For whom is it indicated?
- Patients undergoing pharmacological treatment that does not yield expected results;
- Patients experiencing drug-related side effects.
Technology
Next-generation sequencing (NGS).
FG Onco Lapatinib
Pharmacogenetics of lapatinib treatment
Lapatinib is a medication used in the chemotherapy of breast cancer and other solid tumors. It belongs to the group of kinase inhibitors, which act by blocking the action of the abnormal protein that signals tumor cells to multiply. Several scientific studies show that different HLA (human leukocyte antigen) polymorphisms within the major histocompatibility complex (MHC) are strongly associated with the hepatotoxicity of lapatinib treatment. This hepatotoxicity can appear within a few days or several months after the start of treatment.
The FG Onco Lapatinib genetic profile evaluates whether the patient carries the HLA alleles DQA102:01 and DRB107:01. The purpose of the test is to identify those patients with an increased risk of developing serious side effects, especially hepatotoxicity, during lapatinib treatment.
- Patients undergoing pharmacological treatment that does not yield expected results;
- Patients experiencing drug-related side effects.
Next-generation sequencing (NGS).
Advantages
SYNLAB GROUP
Guaranteed by the experience of the absolute European leader in laboratory diagnostics.
COMPLETE
Detailed report, where the results will suggest individualized courses of action, aiding in prognosis for greater treatment efficacy and a significant reduction in adverse reactions.
Extra Information
DOCUMENTATION – Available on the SYNLAB Direct for clients
- Informed Consent;
- Clinical Questionnaire;
- Medical prescription.
PREPARATION
- Fasting is not necessary for the test.
Delivery Time
12 business days
Sample Type
5mL whole blood in EDTA
Other exams pharmacogenetics:
NEURO PGx
Genetic Analysis of Drug Response
GLOBAL PGx
Genetic Analysis of Drug Response
FG Onco Tamoxifen
Pharmacogenetics of tamoxifen treatment
FG Onco Lapatinib
Pharmacogenetics of lapatinib treatment
FG Cardio Arrhythmia
Pharmacogenetics of Arrhythmias
FG Cardio Hypertension
Pharmacogenetics of Arterial Hypertension
FG Neuro Anxiety
Pharmacogenetics of Anxiety Disorder
FG Neuro Depression
Pharmacogenetics of depressive disorder
FG Neuro Epilepsy
Pharmacogenetics of Epilepsies
FG Neuro Psychosis
Pharmacogenetics of Psychotic Disorders
FG Cardio Completo
Pharmacogenetics in Cardiology
FG Basic
Genetic Analysis of Drug Response